NATHAN OLSON: Open Payments
NPI 1528778859 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$619 in 15 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $22 · 2025 $619
Food & beverage: $619
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $287 |
| AstraZeneca Pharmaceuticals LP | 2 | $143 |
| Insulet Corporation | 1 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Novo Nordisk Inc | 2 | $35 |
| Lilly USA, LLC | 1 | $15 |
Products named: VRAYLAR, FASENRA, QULIPTA, Omnipod, CAPLYTA, Rybelsus, FARXIGA, MOUNJARO.
Industry payments across NE — which companies pay providers there.
